المنـشـــورات Publication 20251Global, Regional, and National Burden of Primary Liver Cancer Attributable to Metabolic Risks: An Analysis of the Global Burden of Disease Study 1990–20212Enhancing the Understanding of Liver Fibrosis in Type 2 Diabetes: Methodological Considerations and Future Directions3Establishing consensus on Arabic medical terminology for steatotic liver disease: a mixed-methods approach4Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 20215Genetic susceptibility of Saudi Population to Hepatitis B Virus (HBV) infection and the predicted functional consequences6MASLD And MASH Risk: Does Losing Obesity Reverse the Metabolic Footprin7Metabolic Dysfunction‐Associated Steatotic Liver Disease in the MENA Region: Setting a Research and Action Priority Agenda8Leading Role of Sofosbuvir/Daclatasvir in Achieving Hepatitis C Elimination in Egypt9Examining pregnancy outcomes in alcohol-associated hepatitis: A call for further research10Revisiting MASLD Nomenclature: Insights from the MENA Region and Its Clinical Relevance11Global burden of major chronic liver diseases in 202112Large annotated ultrasound dataset of non-alcoholic fatty liver from Saudi hospitals for analysis and applications13Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies20241Hybrid Deep Learning and Machine Learning for Detecting Hepatocyte Ballooning in Liver Ultrasound Image2Global burden of disease attributable to metabolic risk factors in adolescents and young adults aged 15–39, 1990–20213Global burden of metabolic diseases, 1990–20214Burden of disease attributable to high body mass index: an analysis of data from the Global Burden of Disease Study 20215Risk Stratification of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease: Steatohepatitis, Fibrosis, and Hepatocellular Carcinoma6Knowledge about metabolic dysfunction-associated steatotic liver disease among the medical professionals from countries in the MENA region7Stigma in steatotic liver disease: A survey of patients from Saudi Arabia8The burden of metabolic dysfunction-associated steatotic liver disease and viral hepatitis in Saudi Arabia9Emerging therapeutic approaches for non-alcoholic fatty liver disease10Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egyp11Validation of FIB-6 score in assessment of liver fibrosis in chronic hepatitis B12The Impact of Stigma on Quality of Life and Liver Disease Burden Among Patients with Nonalcoholic Fatty Liver Disease13Shedding lights on diagnostic challenges in Wilson's disease: The positive impact of introducing steatotic liver disease new nomenclature umbrella.14Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease15A multi-society Delphi consensus statement on new fatty liver disease nomenclature16Steatotic Liver Disease as A New Nomenclature for NAFLD from The Perspectives of The MENA Region: One Size Fits All This Time17Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa20231Hepatocellular Carcinoma: The Role of Immunotherapy and Transplantation in the Era of Transplant Oncology2Evaluation of Quantitative Hepatitis C Virus Core Antigen Testing as a Tool for Screening and Confirmation of HCV Infection.3Multicenter validation of FIB-6 as a novel machine learning non-invasive score to rule out liver cirrhosis in biopsy-proven MAFLD4Surveillance and treatment of primary hepatocellular carcinoma (aka. STOP HCC): protocol for a prospective cohort study of high-risk patients for HCC using GALAD-score5Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries6A global research priority agenda to advance public health responses to fatty liver disease7Clinical and patient-reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry8Nonalcoholic Fatty Liver Disease in Asia, Africa, and Middle East Region9Diabetes mellitus is not associated with worse short term outcome in patients older than 65 years old post-liver transplantation20221Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry2A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease3Molecular Screening via Sanger Sequencing of the Genetic Variants in Non-Alcoholic Fatty Liver Disease Subjects in the Saudi Population: A Hospital-Based Study.4Efficacy of generic sofosbuvir with daclatasvir compared to sofosbuvir/ledipasvir in genotype 4 hepatitis C virus: A prospective comparison with historical control.5Hepatocellular carcinoma in a healthy liver; Case report and literature review.6The future health and economic burden of obesity-attributable type 2 diabetes and liver disease among the working-age population in Saudi Arabia.7Hepatic fibrosis changes in patients with chronic hepatitis C infection who respond to direct-acting antivirals.8Validation of the EVendo score for the prediction of varices in cirrhotic patients.9Association of mitotic checkpoint regulator MAD2L1 with fibrosis progression in chronic hepatitis C patients.10Saudi Association for the Study of Liver diseases and Transplantation position statement on the hepatology workforce in Saudi Arabia.20211Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry2Development and multicenter validation of FIB-6: A novel, machine learning, simple bedside score to rule out liver cirrhosis and compensated advanced chronic liver disease in patients with chronic hepatitis C3Advancing the global public health agenda for NAFLD: a consensus statement4Clinical Practice Guidelines for Liver Transplantation in Saudi Arabia.5Long Term Outcomes of Liver Transplantation For Patients With Autoimmune Hepatitis6Treatment with Grazoprevir/Elbasvir in Post-kidney Transplant Patients with Hepatitis C Virus Genotype 4 Infection7Use of COVID-19 vaccines in patients with liver disease and post-liver transplantation: Position statement of the Saudi association for the study of liver diseases and transplantation8Changing trends in liver transplantation indications in Saudi Arabia: from hepatitis C virus infection to nonalcoholic fatty liver disease9A Global Survey of Physicians Knowledge About Non-alcoholic Fatty Liver Disease10SASLT practice guidelines for the management of Hepatitis B virus – An update11Validating controlled attenuation parameter in the assessment of hepatic steatosis in living liver donors12Clinical and economic burden of nonalcoholic steatohepatitis in SaudiArabia, United Arab Emirates and Kuwait13Epidemiology of Pancreatic Cancer in Saudi Arabia: A Retrospective Analysis of Pancreatic Cancer Diagnosed in Saudi Arabia Between 2004 and 201514Clinical and Metabolic Characteristics of Non-Alcoholic Fatty Liver Disease Patients in Saudi Arabia: Data from the Systematic Observatory Liver Disease (SOLID) Registry20201Revised Nomenclature for Fatty Liver Disease: Cutting through the Confusion2Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa3The case for simplifying and using absolute targets for viral hepatitis elimination goals4In the peripheral blood mononuclear cells (PBMCs) of HCV infected patients the expression of STAT1 and IRF-1 is downregulated while that of caspase-3 upregulated5Management of nonalcoholic fatty liver disease in the Middle East6Saudi association for the study of liver diseases and transplantation position statement on liver transplantation during the COVID-19 pandemic7Prevalence of biopsy-proven nonalcoholic fatty liver among patients with gallstone disease8Principles of Care for Patients with Liver Disease During the Coronavirus Disease 2019 (COVID-19) Pandemic: Position Statement of the Saudi Association for the Study of Liver Disease and Transplantation9Glycogenic Hepatopathy: A Rare Hepatic Complication of Poorly Controlled Type 1 DM10History of Nonalcoholic Fatty Liver Disease11Endothelial dysfunction in nonalcoholic steatohepatitis with low cardiac disease risk12Preparedness and response to COVID-19 in Saudi Arabia: Building on MERS experience13The case for simplifying and using absolute targets for viral hepatitis elimination goals14Outcome of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma20191Clinical and virological outcomes of entecavir therapy in patients with chronic hepatitis B: A real life experience.2The overall survival rate for patients with hepatocellular carcinoma who underwent hepatic resection or radiofrequency ablation procedure for curative intent.3Donor-to-recipient transmission of factor XII deficiency by orthotopic liver transplantation.4Greater prevalence of comorbidities with increasing age: Cross-sectional analysis of chronic hepatitis B patients in Saudi Arabia.5Pancreatic tuberculosis in immunocompetent patients. At the University Hospital in Kingdom of Saudi Arabia.6Position statement on the diagnosis and management of non-alcoholic fatty liver disease.7Association between IL-37 gene polymorphisms and risk of HBV-related liver disease in a Saudi Arabian population.8Molecular epidemiology, phylogenetic analysis and genotype distribution of hepatitis B virus in Saudi Arabia: Predominance of genotype D1.9Genetic variations of NOD2 and MD2 genes in hepatitis B virus infection.10Changes in the patterns and microbiology of spontaneous bacterial peritonitis : analysis of 200 cirrhotic patients.11Quantitative HBsAg levels do not identify hepatic fibrosis in HBeAg-negative chronic hepatitis B patients.12Hepatitis B care pathway in Saudi Arabia: Current situation, gaps and actions.13Clinical and virological outcomes of entecavir therapy in patients with chronic hepatitis B: A real life experience.14Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients.15Pancreatic tuberculosis in immunocompetent patients. At the University Hospital in Kingdom of Saudi Arabia.16Comparison study between open and laparoscopic liver resection in a Saudi tertiary center.17Bariatric surgery effect on patients with nonalcoholic fatty liver disease and type II diabetes mellitus.18Pooled analysis of WHO Surgical Safety Checklist use and mortality after emergency laparotomy.20181Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis.2Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients.3Efficacy and Safety of Simeprevir or Daclatasvir in Combination With Sofosbuvir for the Treatment of Hepatitis C Genotype 4 Infection.4Transient liver dysfunction increases surgical site infections after coronary surgery.5Hajj, Umrah, and the neglected tropical diseases.6Age distribution and outcomes in patients undergoing breast cancer resection in Saudi Arabia. A single-institute study.7Predictors of morbidity and mortality post emergency abdominal surgery: A national study.8Laparoscopy in management of appendicitis in high-, middle-, and low-income countries: a multicenter, prospective, cohort study.9Surgical site infection after gastrointestinal surgery in high-income, middle-income, and low-income countries: a prospective, international, multicentre cohort study.10The Correlation Between Hepatitis B Virus Precore/Core Mutations and the Progression of Severe Liver Disease.11Nonalcoholic fatty liver disease burden – Saudi Arabia and United Arab Emirates, 2017–203012High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1–infected patients with severe chronic kidney disease.13Aggressive Recurrence of Primary Hepatic Epithelioid Haemangioendothelioma after Liver Transplantation.14The Saudi association for the study of liver diseases and transplantation clinical practice guidelines for management of autoimmune hepatitis.20171Treatment of Patients With Hepatitis C Virus Infection With Ledipasvir-Sofosbuvir in the Liver Transplant Setting.2Effect of non-alcoholic liver disease on recurrence rate and liver regeneration after liver resection for colorectal liver metastases.3Adrenocortical carcinoma co-occurrence with a hepatocellular carcinoma within an adrenohepatic fusion: a case report.4Effect of Downstaging and Bridging of Hepatocellular Carcinoma on Survival Following Liver Transplant: A Single Center Experience.5Liver transplantation in the Kingdom of Saudi Arabia.6Low Utility of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography for Detecting Hepatocellular Carcinoma in Patients Before Liver Transplantation.7Strategies to manage hepatitis C virus infection disease burden-Volume 4.8Association of Toll-Like Receptor 3 Single-Nucleotide Polymorphisms and Hepatitis C Virus Infection.9The epidemic dynamics of hepatitis C virus subtypes 4a and 4d in Saudi Arabia.10Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response.11Towards interference free HPLC-SERS for the trace analysis of drug metabolites in biological fluids.12A change roadmap towards research paradigm in low-resource countries: retinoblastoma model in Egypt.13The effects of bariatric surgeries on nonalcoholic fatty liver disease.14Gold nanomaterials for the selective capturing and SERS diagnosis of toxins in aqueous and biological fluids.15An Overview of the Performance Improvement Initiatives by the Ministry of Health in the Kingdom of Saudi Arabia.16Effect of non-alcoholic liver disease on recurrence rate and liver regeneration after liver resection for colorectal liver metastases.17Next generation sequencing of progressive colorectal liver metastases after portal vein embolization.18Acute Pancreatitis: A Complication of Intragastric Balloon.19Evaluation primitive ground water supplies as a risk factor for the development of major waterborne zoonosis in Egyptian children living in rural areas.20Tumor Heterogeneity Predicts Metastatic Potential in Colorectal Cancer.21Failure Mode and Effect Analysis (FMEA) may enhance implementation of clinical practice guidelines: An experience from the Middle East.22High Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir in Hepatitis C Genotypes 4 and 1-infected Patients with Severe Chronic Kidney Disease.23Association of single nucleotide polymorphisms in microRNAs with susceptibility to hepatitis B virus infection and HBV-related liver complications: A study in a Saudi Arabian population.24Hepatitis B virus (HBV) X gene mutations and their association with liver disease progression in HBV-infected patients.25Increased Spontaneous Programmed Cell Death Is Associated with Impaired Cytokine Secretion in Peripheral Blood Mononuclear Cells from Hepatitis C Virus-Positive Patients.26Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4–infected patients with advanced liver fibrosis and decompensated cirrhosis.27Prevalence and Patterns of the use of Protein Supplements among Gym Users in Riyadh, Saudi Arabia.28Pharmacokinetics-Based Adjusted Versus Standard Dose of Ribavirin Does Not Improve Virologic Response Rates in Chronic Hepatitis C Genotype 4 Patients: A Randomized Controlled Trial.29Medical students' perception of the learning environment at King Saud University Medical College, Saudi Arabia, using DREEM Inventory.30Features of nonalcoholic steatohepatitis in severely obese children and adolescents undergoing sleeve gastrectomy.31Increased Spontaneous Programmed Cell Death Is Associated with Impaired Cytokine Secretion in Peripheral Blood Mononuclear Cells from Hepatitis C Virus-Positive Patients.32Improving patient safety culture in Saudi Arabia (2012-2015): trending, improvement and benchmarking.33Magnitude and causes of loss to follow-up among patients with viral hepatitis at a tertiary care hospital in Saudi Arabia.34Diminished accuracy of biomarkers of fibrosis in low replicative chronic hepatitis B.20161Management of hepatitis c genotype 4 in the liver transplant setting.2PARK2 polymorphisms predict disease progression in patients infected with hepatitis C virus.3Aggressive Recurrence of Primary Hepatic Epithelioid Haemangioendothelioma after Liver Transplantation.4Two years' experience of implementing molecular screening of hepatitis B virus, hepatitis C virus and human immunodeficiency virus 1, 2 in Riyadh blood donors.5Surface gene variants of hepatitis B Virus in Saudi Patients.6Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift.7SASLT guidelines: Update in treatment of Hepatitis C virus infection.8Assessment of pro-inflammatory cytokines in sera of patients with hepatitis C virus infection before and after anti-viral therapy.9PARK2 polymorphisms predict disease progression in patients infected with hepatitis C virus.10The impact of metabolic syndrome and prevalent liver disease on living donor liver transplantation: a pressing need to expand the pool.11Medical students' awareness of and compliance with the hepatitis B vaccine in a tertiary care academic hospital: An epidemiological study.12Institutional Research Evaluation Model (IREM): A framework for measuring organizational research trends and impact and its application in medical academia in Saudi Arabia.13Preoperative selection of patients with colorectal cancer liver metastasis for hepatic resection.14GlobalSurg Collaborative. Mortality of emergency abdominal surgery in high-, middle- and low-income countries.15Effect of Insulin Therapy using Hyper-insulinemic Normoglycemic Clamp on Inflammatory Response in Brain Dead Organ Donors.16Trends in brain-dead organ donor characteristics: a 13-year analysis.17Neoadjuvant chemotherapy does not impair liver regeneration following hepatectomy or portal vein embolization for colorectal cancer liver metastases.18Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients.19Colorectal cancer liver metastasis trends in the kingdom of Saudi Arabia.20Use of Lean methodology to improve operating room efficiency in hospitals across the Kingdom of Saudi Arabia.20151Combined fibrosis indices: more than 1 way to skin a cat.2Effect of exposure to silica in inducing autoimmune hepatitis: an experimental animal-controlled study.3Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 3.4The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3.5Strategies to manage hepatitis C virus infection disease burden - volume 3.6Surgical treatment for hepatocellular carcinoma.7Post-transplant venous thromboembolic events and their effect on graft survival.8Portal vein embolization and its effect on tumour progression for colorectal cancer liver metastases.9Decreased PCSK9 expression in human hepatocellular carcinoma.10Portal vein embolization effect on colorectal cancer liver metastasis progression: Lessons learned.11Post-transplant liver function score as an early surrogate marker of long-term outcome.12Cerebral Hemodynamics Patterns by Transcranial Doppler in Patients With Acute Liver Failure.13The very-rapid and the ultra-rapid virologic response to two treatment options in patients with chronic hepatitis C: an interim report of a prospective randomized comparative effectiveness study.14Hepatocellular Carcinoma Occurs at an Earlier Age in Africans, Particularly in Association With Chronic Hepatitis B.15The role of Fibroscan in predicting the presence of varices in patients with cirrhosis.16Viral hepatitis in Saudi Arabia. An unfinished story.17Correlation between genetic variations and serum level of interleukin 28B with virus genotypes and disease progression in chronic hepatitis C virus infection.18Autologous Bone Marrow–Derived Cells in the Treatment of Liver Disease Patients.19Aggressive recurrence of primary hepatic epithelioid hemangioendothelioma after liver transplantation.20Normal liver stiffness: A study in living donors with normal liver histology.21SASLT position statement on the direct-acting antiviral agents for the treatment of hepatitis C virus infection.22Spontaneous clearance of hepatitis C genotype 4 after liver retransplantation.23Nonalcoholic fatty liver disease: Noninvasive methods of diagnosing hepatic steatosis.24Hemobilia post laparoscopic cholecystectomy.25Hyponatremia as the Initial Presentation of Cryptococcal Meningitis After Liver Transplantation.
